In the large international phase III MAVORIC trial, patients with previously 
treated cutaneous T-cell lymphoma who received the anti-CCR4 monoclonal antibody 
mogamulizumab experienced significantly longer progression-free survival and 
higher response rates, as well as better quality of life, than those who 
received vorinostat, a standard therapy.